Advertisement
The new Pharmacor report Insomnia finds that the 5-HT2 antagonisteplivanserin and the orexin receptor antagonist ACT-078573 are among 11emerging therapies for insomnia that will enter the market during the nextdecade. Among the emerging therapies will be the launches (outside the UnitedStates) of Sepracor's Lunesta and Takeda's Ramelteon, both of which areforecasted to launch in Europe in 2008 and in Japan in 2010. Experts believethat the broadening recognition of insomnia as a treatable disorder byphysicians and patients will help drive market growth in the United States,France, Germany, Italy, Spain, the United Kingdom, and Japan.
Advertisement
The report finds that steadily growing diagnosis and drug-treatment rates,combined with a prevalent population of 140 million, make insomnia one of thefew remaining markets with blockbuster potential. However, the availability ofgeneric Ambien, combined with increased regulatory scrutiny for insomniatherapies, will constrain overall market sales.
"Compared with other large psychiatric markets, insomnia calls for agentsthat are more clearly differentiated from current drugs," said Natalie Taylor,Ph.D., analyst at Decision Resources. "Heightened regulatory benchmarks fornew therapies and the generic availability of the well-entrenched Ambien willcurtail the blockbuster potential of 'me-too' agents that do not clearlydemonstrate advantages in safety and efficacy. Drugs with clinical trial dataestablishing efficacy in various insomnia populations-such as those withunderlying psychiatric disorders, the elderly, and patients with chronicinsomnia-will have the most commercial potential."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources
